This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Zibotentan
DrugBank Accession Number
DB06629
Background

Not Available

Type
Small Molecule
Groups
Investigational
Structure
Weight
Average: 424.44
Monoisotopic: 424.095374193
Chemical Formula
C19H16N6O4S
Synonyms
  • Zibotentan
External IDs
  • AZD-4054
  • ZD-4054
  • ZD4054

Pharmacology

Indication

Investigated for use/treatment in prostate cancer.

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Not Available
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as phenylpyridines. These are polycyclic aromatic compounds containing a benzene ring linked to a pyridine ring through a CC or CN bond.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Pyridines and derivatives
Sub Class
Phenylpyridines
Direct Parent
Phenylpyridines
Alternative Parents
Pyridinesulfonamides / Methoxypyrazines / Alkyl aryl ethers / Organosulfonamides / Imidolactams / Benzene and substituted derivatives / Heteroaromatic compounds / Aminosulfonyl compounds / 1,3,4-oxadiazoles / Oxacyclic compounds
show 5 more
Substituents
1,3,4-oxadiazole / 2-phenylpyridine / Alkyl aryl ether / Aminosulfonyl compound / Aromatic heteromonocyclic compound / Azacycle / Azole / Benzenoid / Ether / Heteroaromatic compound
show 19 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
8054MM4902
CAS number
186497-07-4
InChI Key
FJHHZXWJVIEFGJ-UHFFFAOYSA-N
InChI
InChI=1S/C19H16N6O4S/c1-12-10-21-17(19(23-12)28-2)25-30(26,27)15-4-3-9-20-16(15)13-5-7-14(8-6-13)18-24-22-11-29-18/h3-11H,1-2H3,(H,21,25)
IUPAC Name
N-(3-methoxy-5-methylpyrazin-2-yl)-2-[4-(1,3,4-oxadiazol-2-yl)phenyl]pyridine-3-sulfonamide
SMILES
COC1=NC(C)=CN=C1NS(=O)(=O)C1=CC=CN=C1C1=CC=C(C=C1)C1=NN=CO1

References

General References
Not Available
ChemSpider
8085875
ChEBI
94573
ChEMBL
CHEMBL1628688
ZINC
ZINC000001491485
Wikipedia
Zibotentan

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedTreatmentProstate Cancer2
3TerminatedTreatmentProstate Cancer1
2CompletedBasic ScienceIntermittent Claudication / Peripheral Arterial Disease (PAD)1
2CompletedTreatmentChronic Kidney Disease (CKD) / Scleroderma / Scleroderma Renal Crisis1
2CompletedTreatmentColorectal Cancer1
2CompletedTreatmentLung Cancers / Non-Small Cell Lung Carcinoma (NSCLC)1
2CompletedTreatmentNeoplasm Metastases / Prostatic Neoplasms1
2CompletedTreatmentProstate Cancer1
2Not Yet RecruitingScreeningCirrhosis of the Liver1
2RecruitingTreatmentChronic Kidney Disease (CKD)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.177 mg/mLALOGPS
logP2.33ALOGPS
logP1.01ChemAxon
logS-3.4ALOGPS
pKa (Strongest Acidic)5.46ChemAxon
pKa (Strongest Basic)0.92ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area132.99 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity118.89 m3·mol-1ChemAxon
Polarizability42.05 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created at March 19, 2008 16:41 / Updated at February 21, 2021 18:52